symptoms are triggered by calcitonin gene - binding peptide ( CGRP ) protein . This widens blood vessels near to the nerves in the head , causing pain . The new treatment uses monoclonal blood protein compounds . These are genetically engineered to bind to CGRP and successfully ' clean it up ' Trials found the treatment significantly reduced migraines in sufferers .
Migraines are triggered by calcitonin gene-related peptide ( CGRP ) protein . This widens blood vessels near to the nerves in the head , causing pain . The new injection contains monoclonal blood protein compounds . These are antibodies engineered to bind to CGRP and can 'mop it up ' Trials found the treatment significantly reduced migraines in sufferers .